Compare Estee Lauder Companies Inc (EL) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Organon & Co. Common Stock — how do they compare? Estee Lauder Companies Inc trades at $101.66 (market cap $36.13B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Estee Lauder Companies Inc is far larger — about 10× Organon & Co. Common Stock's market cap, and Estee Lauder Companies Inc pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Organon & Co. Common Stock for 0 Days on average.
| EL | OGN | |
|---|---|---|
Market Cap | $36.13B | $3.62B |
Volume | 1,925,948 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $13.81 |
52-Week Low | $67.23 | $5.70 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $41.88B | $11.04B |
Dividend Yield | 1.4% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $101.59, up 1.55% with strong technical momentum and bullish moving average signals. The company shows improving operational trends with three consecutive quarterly earnings beats, though 2025 results reflect a net loss of $1.13B amid revenue contraction. Recent strategic partnerships in AI marketing and leadership appointments signal transformation efforts, while analyst consensus remains positive with a $103 price target.
The stock presents a turnaround opportunity with margin recovery potential and digital innovation initiatives, but faces execution risks from competitive pressures and debt levels. Current valuation multiples appear elevated relative to profitability metrics, requiring careful monitoring of Q3 2026 earnings delivery for confirmation of sustained improvement.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
